Colleen Kelley, MD, MPH
Faculty member in the Division of Infectious Diseases with a secondary appointment in the Department of Epidemiology, Rollins School of Public Health, Emory University
Principal investigator on the PURPOSE 2 trial
Articles
June 20th 2025
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Latest Updated Articles
Published: June 27th 2025 | Updated: July 1st 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health System
Published: February 20th 2025 | Updated: February 21st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
